This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Peter B. Crino; M. David Ullman, PhD; Brent A. Vogt, PhD; Edward D. Bird, MD; Ladislav Volicer, MD, PhD

Arch Neurol. 1989;46(4):398-401.

Abstract
• Gangliosides GM₁, GD_1a, GD_1b, and GT_1b were measured in nine brain regions of five patients, clinically and neuropathologically diagnosed as having dementia of the Alzheimer type (DAT), and of three control patients. Analysis of variance revealed that mean concentrations of all gangliosides analyzed were significantly lower in DAT than in control brains. The areas affected in DAT included the nucleus basalis, and entorhinal, posterior cingulate, visual, and prefrontal cortices. A significant interaction between ganglioside type and brain area indicated unequal ganglioside concentrations. Individual gangliosides had significantly different concentrations in the hippocampal, entorhinal, posterior cingulate, visual, and prefrontal cortices. Analysis of ratios of "a"-ganglioside (GM₁ and GD_1a) and "b"-ganglioside (GD_1b and GT_1b) subtypes indicated that DAT preferentially affected "b"-gangliosides. Ganglioside concentrations in nucleus basalis did not correlate with age at disease onset, age at death, or postmortem interval. Changes in gangliosides, observed in this study, were not correlated with classic DAT neuropathology.

Author Affiliations
From the E. N. Rogers Memorial Veterans Hospital, Geriatric Research Education Clinical Center, Bedford, Mass (Mr Crino, and Drs Ullman, Vogt, and Volicer); Departments of Behavioral Neuroscience (Mr Crino), Psychiatry (Dr Volicer), Anatomy (Dr Vogt), and Pharmacology (Dr Volicer), Boston (Mass) University School of Medicine; and Mailman Research Center, McLean Hospital, Belmont (Dr Bird), Mass.

Footnotes
Accepted for publication October 19, 1988.

Presented at the 17th Annual Meeting of the Society for Neuroscience, New Orleans, La, November 18, 1987.

Reprint requests to E. N. Rogers Memorial Veterans Hospital, Geriatric Research Education Clinical Center, 200 Springs Rd, Bedford, MA 01730 (Dr Volicer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Thematic Review Series: Sphingolipids. Role of ganglioside metabolism in the pathogenesis of Alzheimer's disease--a review
Ariga et al.
J. Lipid Res. 2008;49:1157-1175.
ABSTRACT | FULL TEXT  

Role of sphingolipid-mediated cell death in neurodegenerative diseases
Ariga et al.
J. Lipid Res. 1998;39:1-16.
ABSTRACT | FULL TEXT  

Changes in Tardive Dyskinesia Symptoms in Elderly Patients Treated with Ganglioside GM1 or Placebo
Sommer et al.
J Geriatr Psychiatry Neurol 1994;7:234-237.
ABSTRACT